HOME >> MEDICINE >> NEWS
Misconceptions about sexual violence common among South African youth

Misconceptions about sexual violence and the risk of HIV infection and AIDS are common among South African youth, finds a study in this week's BMJ.

Researchers surveyed over 269,000 South African school pupils aged 10-19 years about their views on and experiences of sexual violence.

Misconceptions about sexual violence were common among both sexes, but more females held views that would put them at high risk of HIV infection.

Around 11% of males and 4% of females claimed to have forced someone else to have sex. Most of these had themselves been forced to have sex, suggesting that a history of forced sex distorted perceptions about sexual violence and risk of HIV infection.

One in three youth believed they could be HIV positive. One in four of these had not even had sex, an indicator of ignorance of the mechanism of HIV infection, say the authors. This failure of education comes at an important cost: youth who believed they were HIV positive had misconceptions similar to those who had forced someone else to have sex.

The views of South African youth on sexual violence and on the risk of HIV infection and AIDS were compatible with acceptance of sexual coercion and "adaptive" attitudes to survival in a violent society, conclude the authors.


'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
21-Oct-2004


Page: 1

Related medicine news :

1. Opponents of needle-exchange programs should think about their message to drug users
2. US life expectancy about to decline, researchers say
3. Most hospital executives have substantial concerns about mandatory error reporting systems
4. Rhesus monkeys reason about perspectives of others in obtaining food
5. Antimicrobials to prevent infection in major surgery are used properly only about half the time
6. Risk factors affect parents attitudes about STD vaccinations
7. Parents have complex opinions about notification laws for minors access to contraception
8. Article highlights confusion about Homeland Security safety symbols
9. Carefree people care less about cancer symptoms, endanger health
10. Pediatricians wary about recommending complementary therapies
11. New study lays to rest concerns about virtual colonoscopy as a screening tool

Post Your Comments:
(Date:6/19/2013)... 2013 Maui'd Forever , Hawaii's ... being an effective and cost effective way to provide ... partnered up with Tom Barefoot’s Tours providing an activity ... of Hawaii’s activities. , They have just released a ... the lowest prices on their Hawaii activities. , ...
(Date:6/19/2013)... June 19, 2013 According to Transparency ... Market Share, Trends, Analysis and Forecast, 2011 – 2017,” ... billion in the year 2011 and is expected to ... CAGR of 9.7% from 2011 to 2017. Flexible endoscopes ... contributing about USD 2,201 million for the year 2011. ...
(Date:6/19/2013)... neurologists treating stroke victims has been "time equals brain." That,s ... receive a drug that dissolves the stroke-causing blood clot can ... saved or lost. , But specific information has ... intravenous drug known as a tissue plasminogen activator, or ... the most common type of stroke. , Now, ...
(Date:6/19/2013)... Il. A Loyola University Chicago Niehoff School of ... to study whether Vitamin D can improve mood in ... also will examine whether vitamin D supplementation can reduce ... diabetes. The grant is from the National Institute of ... Principal investigator Sue M. Penckofer, PhD, RN and colleagues ...
(Date:6/19/2013)... June 19, 2013 AquaPrint Solutions in Thomson, ... & Grub with a newly-designed Harley Davidson motorcycle gas tank. ... AquaPrint Solutions with an idea of taking a split tank ... ages and transforming it into a work of art. ... & Grub several toilet seats that had been dipped in ...
Breaking Medicine News(10 mins):Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)...  Decision Resources, one of the world,s leading ... issues, finds that, for the treatment of rheumatoid ... rheumatologists cite a therapy,s induction of remission as ... prescribing decisions. Over 60 percent and 70 percent ... percentage of patients achieving remission at six months ...
(Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics ... from a human abuse liability (HAL) study for NKTR-181, ... of entry into the brain.  This slow rate of entry ... the abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and ...
Breaking Medicine Technology:Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
Cached News: